
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna is a commercial-stage biotech that specializes in developing transformative medicines based on mRNA technology. With 35 mRNA development candidates in clinical studies, the firm has a wide range of potential treatments in its pipeline, including for infectious diseases, oncology, cardiovascular disease, and rare genetic diseases. The company's success with its COVID-19 vaccine has led to significant revenue and opportunities for growth, such as in the flu and RSV markets. In addition to its strong current product offerings, Moderna also has promising early-stage programs for rare diseases and potential for its cancer vaccine to become the next PD-1. However, there are risks to consider, such as potential clinical failures and pricing pressure in the market, which may impact the company's financial performance.
Bears say
Moderna is a commercial-stage biotech with a negative outlook due to potential competition, regulatory uncertainties, and long-term pricing pressure in the space. While the company has shown progress and has a diversified pipeline, its recent IP settlement and market cap of $18 billion may present a balanced risk/reward ratio for investors. With many promising programs in various stages of development, Moderna will continue to face competition in the rapidly evolving biotech industry.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares